RemeGen Co., Ltd.
Other OTCTotal Valuation
RemeGen Co., Ltd. carries a market capitalization of 6.79B, placing it among publicly traded companies globally. Its enterprise value stands at 1.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.79B |
| Enterprise Value | 1.52B |
Share Statistics
RemeGen Co., Ltd. currently has 544.26M shares outstanding.
| Shares Outstanding | 544.26M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 4.35 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 5.29 |
Financial Position
RemeGen Co., Ltd. maintains a current ratio of 1.51, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 90.00, indicating elevated leverage, while an interest coverage ratio of -40.74 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.51 |
| Quick Ratio | 0.53 |
| Debt / Equity | 90.00 |
| Debt / EBITDA | -7.69 |
| Interest Coverage | -40.74 |
Financial Efficiency
| Return on Equity (ROE) | -307.55 |
| Return on Assets (ROA) | -66.99 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.70 |
Stock Price Statistics
RemeGen Co., Ltd.'s stock has gained approximately 138.14229% over the past 52 weeks. The 50-day moving average sits at 11.44, while the 200-day moving average is 9.76.
| Beta (5Y) | N/A |
| 52-Week Price Change | 138.14229% |
| 50-Day Moving Average | 11.44 |
| 200-Day Moving Average | 9.76 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, RemeGen Co., Ltd. generated 350.40M in revenue and converted that into -327.22M in net income, yielding earnings per share of -0.61. EBITDA reached -312.03M, while operating income came in at -312.03M.
| Revenue | 350.40M |
| Gross Profit | 275.25M |
| Operating Income | -312.03M |
| Pretax Income | -327.22M |
| Net Income | -327.22M |
| EBITDA | -312.03M |
| EBIT | -312.03M |
| Earnings Per Share (EPS) | -0.61 |
Balance Sheet
RemeGen Co., Ltd. holds 873.56M in cash and equivalents against 2.40B in total debt, resulting in a net debt position of 1.60B. Total book value stands at -3.09B, with working capital of 845.45M providing operational flexibility.
| Cash & Cash Equivalents | 873.56M |
| Total Debt | 2.40B |
| Net Debt | 1.60B |
| Equity (Book Value) | -3.09B |
| Book Value Per Share | -5.76 |
| Working Capital | 845.45M |
Cash Flow
After subtracting -280.75M in capital expenditures, free cash flow totaled -280.75M - equivalent to -0.52 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -280.75M |
| Free Cash Flow | -280.75M |
| FCF Per Share | -0.52 |
Margins
RemeGen Co., Ltd. operates with a gross margin of 78.55, reflecting its pricing power and cost economics. The operating margin of -89.05 and net profit margin of -93.39 provide insight into operational efficiency.
| Gross Margin | 78.55 |
| Operating Margin | -89.05 |
| Pretax Margin | -93.39 |
| Profit Margin | -93.39 |
| EBITDA Margin | -89.05 |
Scores
RemeGen Co., Ltd. posts an Altman Z-Score of -0.83, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.83 |